Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 3.99 -0.05 (-1.24%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Arena Pharmaceutical's Belviq Requires Patience And Understanding (ARNA)
As someone with a relatively oversized long position in Arena Pharmaceuticals (NASDAQ:ARNA) I have been somewhat disappointed in the performance of both the stock and Arena's flagship offering, Belviq. Since the launch of Belviq in the late Spring of ...
Related articles »  
Arena Pharmaceuticals (ARNA) Granted US Patent For Ralinepag
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced yesterday that it been granted composition of matter patent by the US Patent and Trademark Office for its pipeline drug ralinepag for the treatment of vasospastic diseases, including pulmonary ...
Stocks Highlights - Arena Pharmaceuticals, Inc (NASDAQ:ARNA), New York ...  Techsonian (press release)
Related articles »  
Arena's Belviq - Regulatory Update And A Recall (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) filed an 8K with the SEC on Friday, offering news of regulatory updates and informing investors of a recall on the anti-obesity drug Belviq.
Related articles »  
Arena: Belviq Sales See Pleasant Rebound
In my opinion, the impacts of the Belviq recall, announced by Arena Pharmaceuticals (NASDAQ:ARNA) last Friday, carried a small impact on the script numbers this week.
Related articles »  
Belviq Sales About What Was Expected For Thanksgiving Week (ARNA)
Belviq, the anti-obesity medication from Arena Pharmaceuticals (NASDAQ:ARNA), saw its week over week scripts drop with this week's numbers.
Related articles »  
Momentum Stocks in Focus: Arena Pharmaceuticals, Inc.(ARNA), Ascena Retail ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA)increased 3.69% and closed at $4.04 in the last trading session with the overall traded volume of 2.24 million shares, versus the average volume of 3.23 million shares.
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare ...
SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, +3.59% announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, ...
Related articles »  
Movers to Watch: Arena Pharmaceuticals, Inc. (ARNA), Comstock Resources Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)decreased -4.86% and closed at $3.72 in the last trading session with the overall traded volume of 3.52 million shares, versus the average volume of 3.80 million shares.
Related articles »  
Arena Pharmaceuticals Inc.: Arena Pharmaceuticals Issued Composition of ...
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S.
Arena Pharma granted patent for pulmonary hypertension drug  San Diego Source (subscription)
Related articles »